These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19796564)

  • 1. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis.
    Allanore Y; Meune C
    Clin Exp Rheumatol; 2009; 27(3 Suppl 54):59-63. PubMed ID: 19796564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment?
    Allanore Y; Wahbi K; Borderie D; Weber S; Kahan A; Meune C
    Ann Rheum Dis; 2009 Dec; 68(12):1885-9. PubMed ID: 19054819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis.
    Cavagna L; Caporali R; Klersy C; Ghio S; Albertini R; Scelsi L; Moratti R; Bonino C; Montecucco C
    J Rheumatol; 2010 Oct; 37(10):2064-70. PubMed ID: 20634241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac biomarkers in systemic sclerosis: contribution of high-sensitivity cardiac troponin in addition to N-terminal pro-brain natriuretic peptide.
    Avouac J; Meune C; Chenevier-Gobeaux C; Borderie D; Lefevre G; Kahan A; Allanore Y
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):1022-30. PubMed ID: 25604469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: a single centre study.
    Költő G; Vuolteenaho O; Szokodi I; Faludi R; Tornyos A; Ruskoaho H; Minier T; Czirják L; Komócsi A
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-75-81. PubMed ID: 25372791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction.
    Dimitroulas T; Giannakoulas G; Papadopoulou K; Karvounis H; Dimitroula H; Koliakos G; Karamitsos T; Parcharidou D; Settas L
    J Rheumatol; 2010 May; 37(5):993-9. PubMed ID: 20194451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
    Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
    Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurohormonal activation in patients with systemic sclerosis-related pulmonary arterial hypertension.
    Dimitroulas T; Giannakoulas G; Karvounis H; Sfetsios T; Koliakos G; Parcharidis G; Settas L
    Int J Cardiol; 2007 Sep; 121(1):135-7. PubMed ID: 17088004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure.
    McKie PM; Rodeheffer RJ; Cataliotti A; Martin FL; Urban LH; Mahoney DW; Jacobsen SJ; Redfield MM; Burnett JC
    Hypertension; 2006 May; 47(5):874-80. PubMed ID: 16585413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are troponin and B-type natriuretic peptides useful biomarkers for the diagnosis of systemic sclerosis heart involvement? A systematic literature review.
    Ross L; Moxey J; Nikpour M
    Semin Arthritis Rheum; 2021 Feb; 51(1):299-309. PubMed ID: 33434765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers.
    Allanore Y; Borderie D; Meune C; Cabanes L; Weber S; Ekindjian OG; Kahan A
    Arthritis Rheum; 2003 Dec; 48(12):3503-8. PubMed ID: 14674001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcome in systemic sclerosis.
    Voilliot D; Magne J; Dulgheru R; Kou S; Henri C; Caballero L; De Sousa C; Sprynger M; Andre B; Pierard LA; Lancellotti P
    Acta Cardiol; 2015 Oct; 70(5):554-63. PubMed ID: 26567815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of N-terminal pro-brain natriuretic peptide in detecting clinically significant cardiac involvement in systemic sclerosis patients.
    Chighizola C; Meroni PL; Schreiber BE; Coghlan JG; Denton CP; Ong VH
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S81-5. PubMed ID: 22691215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of B-type natriuretic peptides in detecting latent left ventricular diastolic dysfunction in beta-thalassemia major.
    Kremastinos DT; Hamodraka E; Parissis J; Tsiapras D; Dima K; Maisel A
    Am Heart J; 2010 Jan; 159(1):68-74. PubMed ID: 20102869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natriuretic peptides in heart failure and acute coronary syndrome.
    Gaggin HK; Januzzi JL
    Clin Lab Med; 2014 Mar; 34(1):43-58, vi. PubMed ID: 24507786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between interleukin-6 and cardiac involvement in systemic sclerosis.
    Jurisic Z; Martinovic-Kaliterna D; Marasovic-Krstulovic D; Perkovic D; Tandara L; Salamunic I; Carevic V
    Rheumatology (Oxford); 2013 Jul; 52(7):1298-302. PubMed ID: 23538743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left heart disease: a frequent cause of early pulmonary hypertension in systemic sclerosis, unrelated to elevated NT-proBNP levels or overt cardiac fibrosis but associated with increased levels of MR-proANP and MR-proADM: retrospective analysis of a French Canadian cohort.
    Miller L; Chartrand S; Koenig M; Goulet JR; Rich É; Chin AS; Chartrand-Lefebvre C; Abrahamowicz M; Senécal JL; Grodzicky T
    Scand J Rheumatol; 2014; 43(4):314-23. PubMed ID: 25089008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased serum level of N-terminal Pro-B-type natriuretic peptide as a possible biomarker of cardiovascular risk in psoriatic patients.
    Pietrzak A; Bartosinska J; Blaszczyk R; Chodorowska G; Brzozowski W; Hercogova J; Donica H; Lotti T
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):1010-4. PubMed ID: 24735175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in the elderly].
    Guillaumou G; Celton B; Ferreira E; Ventura E; Reygrobellet P; Durant R
    Rev Med Interne; 2009 Aug; 30(8):678-85. PubMed ID: 19100664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.